4D Pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of Live Biotherapeutics, is pleased to announce the appointment of N+1 Singer as Nominated Adviser and Joint Broker to the Company with immediate effect.
N+1 Singer is acting as Nominated Adviser and Joint Broker alongside Bryan Garnier & Co. Limited.
About 4D Pharma
Founded in February 2014, 4D Pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D Pharma has developed a proprietary platform that rationally identifies novel bacteria based on a deep understanding of function and mechanism. 4D Pharma’s Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D Pharma has three clinical studies in progress, namely a Phase II clinical study of Blautix® in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours and a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. Other focus programmes include disease areas such as asthma and CNS disease.
Market Cap: £62 million*
Website: Click here
*As at 28/06/2019
For more information on this news, please email us or call us on +44 (0)20 7496 3000.